THERAPY DOSSIER · th-2a4c19863bf7

Nanoconjugate-bound 1,3-dipropyl-8-cyclopentylxanthine (DPCPX)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28223038 ↗2017Reported benefit

Nanoconjugate-bound adenosine Areceptor antagonist enhances recovery of breathing following acute cervical spinal cord injury.

RatSpinal cord injuryHemisection / partialSprague-DawleyMaleIntradiaphragmatic0.15 microgram/kgGiven at the time of the C2 hemisection on day 0

Model: C2 spinal cord hemisection (cervical hemisection) on day 0

A single intradiaphragmatic administration of nanoconjugate-bound DPCPX facilitated recovery of tidal volume and minute ventilation after cervical spinal cord injury in unanaesthetised rats and attenuated the injury-associated increase in respiratory frequency.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…